Author Archives | BeckyShadle
BeckyShadle - who has written 34 posts on FavStocks.
A business savvy Seattle native who has run a successful Seattle based business for 9 years. Becky likes to keep a close watch on the Biotechnolgy sector and maintains long term hold positions (20% portfolio) and enjoys the high risks and the lucrative returns.
She likes to keep watch on companies in all stages of FDA drug approval. Combining key information with an unemotional view she hopes that you might be able to spot some big opportunities in the biotech sector.
Enzo Biochem at Bio-Europe 2009 (NYSE:ENZ)
Speaking at the Bio-Europe 2009 Conference in Austria, Enzo Biochem, Inc (NYSE:ENZ) announced that the Company’s therapeutic platforms are utilizing oral immune regulation for immune mediated diseases.
Continue reading...UNDT’s Black Mold Detection (OTC:UNDT)
4 November 2009
Comments Off
Universal Detection Technology (OTC:UNDT) has announced that they are expanding their product catalogue which will now include a consumer ready kit for the detection of black mold.
Continue reading...Gilead Sciences Combination Therapy (NASDAQ:GILD)
3 November 2009
Comments Off
Gilead Sciences, Inc. (NASDAQ:GILD) in partnership with the GlaxoSmithKline plc (ADR) (NYSE:GSK)Â today has announced their plans for an international clinical trial to study the combination therapy versus monotherapy in a first-line treatment setting for pulmonary arterial hypertension (PAH).
Continue reading...BSD Medical’s Hyperthermia Therapy (NASDAQ:BSDM)
30 October 2009
Comments Off
BSD Medical Corporation (NASDAQ:BSDM) today announced that their published study results demonstrated improvement in the overall survival, tumor response rates, and local tumor control from the addition of hyperthermia therapy delivered through BSD-2000 Hyperthermia System. This therapy was delivered as a standard treatment regimen for the 45 patients suffering from high-risk bladder cancer.
Continue reading...Celera and Medical Therapies (NASDAQ:CRA)
30 October 2009
Comments Off
On a late Thursday evening, Celera Corporation (NASDAQ:CRA) and Medical Therapies Limited have announced that they have entered an exclusive license agreement for the use of Medical Therapies’ midkine patent portfolio for the development of novel lung cancer diagnostics.
Continue reading...CytRx’s Seeking Destruction Of Cancer Cells (NASDAQ:CYTR)
29 October 2009
Comments Off
CytRx Corporation (NASDAQ:CYTR) has announced that a paper published in Gerontology journal concluded that molecular chaperone amplification may represent a significant strategy in the designing of anti-aging pharmaceuticals in the near future.
Continue reading...Columbia Laboratories Registered Direct Offering (NASDAQ:CBRX)
29 October 2009
Comments Off
Columbia Laboratories, Inc. (NASDAQ:CBRX), a company that is into the development, manufacturing and commercialization of pharmaceutical products has successfully raised around $11,772,000 in gross proceeds through the sale of 10,900,000 shares of its common stock and warrants to purchase 5,450,000 shares of its common stock in a registered direct offering.
Continue reading...GSK Arzerra Approved (NYSE:GSK)
27 October 2009
Comments Off
On Monday morning, the Food and Drug Administration panel approved Arzerra, a leukemia treatment that will be marketed and commercialized by GlaxoSmithKline Plc (ADR) (NYSE:GSK).
Continue reading...Alcon Takes Over Potentia (NYSE:ACL)
26 October 2009
Comments Off
Alcon, Inc. (NYSE:ACL) has announced that they have inked a licensing and purchasing agreement with Potentia Pharmaceuticals.
Continue reading...AstraZeneca and Bristol-Myers report mixed data (BMY, AZN)
22 October 2009
Comments Off
It was just three weeks ago when AstraZeneca and Bristol-Myers Squibb came up with an announcement that their new diabetes drug named Dapagliflozin has come up with positive results in the late-stage trial that combined the therapy with metformin, a standard therapy.
Continue reading...
5 November 2009
Comments Off